CC-1065 and the duocarmycins: recent developments

Bibliography

• HANKA LI DIETZ A, GERPHEIDE SA, KUENTZEL SL, MARTIN DG: CC-1065 (NSC-298223) a new antitumor antibiotic. Production, in vitro biological activity, microbiological assays and taxonomy of the producing microorganism. J. Antibiot. (1978) 31:1211–1217.
   Google Scholar
• MARTIN DG, CHIDESTER CG, DUCHAMP DJ, MIZSAK SA: Structure of CC-1065 (NSC 298223), a new antitumor antibiotic. J Ant/blot. (1980) 33:902–903.
   Google Scholar
• MARTIN DG, BILES C, GERPHEIDE SA, HANKA LJ, KRUEGER WC, MCGOVERN JP et al: CC-1065 (NSC 298223), a potent new antitumor agent improved production and isolation, characterization and antitumor activity. J Antibiot. (1981) 34:1119–1125.
   PubMed Web of Science ®Google Scholar
• CHIDESTER CG, KRUEGER WC, MIZSAK SA, DUCHAMP DJ, MARTIN DG: The structure of CC-1065, a potent antitumor agent and its binding to DNA. J. Am. Chem. Soc. (1981) 103:76297–635.
   Google Scholar
• TAKAHASHI I, TAKAHASHI K, ICHIMURA M et al.:Duocarmycin A, a new antibiotic from Streptomyces.J. Antibiot (1988) 41:1915–1917.
   Google Scholar
• YASUZAWA T, IIDA T, ICHIMURA M, TAKAHASHI K, SANO H: Structure of duocarmycins produced by Strepto-myces sp. Chem. Pharm. Bull. (1988) 36:3728–3731.
   PubMedGoogle Scholar
• ICHIMURA M, MUROI K, ASANO K, KAWAMOTO I, TOMITA F, MORIMOTO M et al.: DC89-A1, a new antitumor antibiotic from Streptomyces. j Antibiot. (1988) 41:1285–1288.
   PubMedGoogle Scholar
• OHBA K, WATABE H, SASAKI T, TAKEUCHI Y, KODAMAY, NAKAZAWA T: Pyrindamycins A and B, new antitumor antibiotics. J. Antibiot (1988) 41:1515–1519.
   PubMedGoogle Scholar
• OGAWA T, ICHIMURA M, KATSUMATA S, MORIMOTO M,TAKAHASHI, K: New antitumor antibiotics, duocarmycins B1 and B2. J. Antibiot. (1989) 42:1299–1301.
   PubMedGoogle Scholar
• ISHII S, NAGASAWA M, KARIYA Y, YAMAMOTO H, INOUYE S, KONDO S: Antitumor activity of pyrinda-mycins A and B. J Antibiot. (1989) 42:1713–1717.
   PubMedGoogle Scholar
• ICHIMURA M, OGAWA T, TAKAHASHI K et al.: Duocarmycin SA, a new antitumor antibiotic from Streptomyces sp . j Antibiot (1990) 43:1037–1038.
   PubMedGoogle Scholar
• YASUZAWA T, SITOH Y, ICHIMURA M, TAKAHASHI I, SANO H: Structure of duocarmycin SA, a potent antitumor antibiotic. J Antibiot. (1991) 44:445–447.
   PubMedGoogle Scholar
• ICHIMURA M, OGAWA T, KATSUMATA S, TAKAHASHI K,TAKAHASHI I, NAKANO H: Duocarmycins, new antitumor antibiotics produced by Streptomyces; producing organisms and improved production. J Antibiot (1991) 44:1045–1053.
   PubMedGoogle Scholar
• YASUZAWA T, MUROI K, ICHIMURA M et al.: Duocarmycins, potent antitumor antibiotics produced by Streptomyces sp. structures and chemistry. Chem. Pharm. Bull. (1995) 43:378–391.
   PubMedGoogle Scholar
• BOGER DL, JOHNSON DS: CC-1065 and theduocarmycins: unravelling the keys to a new class of naturally derived DNA alkylating agents. Proc. Natl. Acad. ScL USA (1995) 92:3642–3649.
   PubMed Web of Science ®Google Scholar
• BOGER DL: The duocarmycins: synthetic andmechanistic studies. Acc. Chem. Res. (1995) 28:20–29.
   Google Scholar
• •The report describes the mechanism of action of CC-1065 and duocarmycins.
   Google Scholar
• BOGER DL: Duocarmycins: a new class of sequence selective DNA minor groove alkylating agents. chemtracts: Org. Chem. (1991) 4:329–349.
   Google Scholar
• BOGER DL: Design, synthesis and evaluation of functional analogs of CC-1065 and the duocarmycins: a study of structural features effecting DNA binding selectivity. Adv. Heterocycl. Nat. Prod. Synth. (1992) 2:1–188.
   Google Scholar
• WARPEHOSKI MA: Dissecting the complex structure of CC-1065. Drugs Fut. (1991) 16:131–141.
   Google Scholar
• WARPEHOSKI MA, HURLEY LH: Sequence selectivity of DNA covalent modification. Chem. Res. Toxicol (1988) 1:315–333.
   PubMed Web of Science ®Google Scholar
• HURLEY LH, NEEDHAM-VANDEVANTER DR: Covalent binding of antitumor antibiotics in the minor groove of DNA. Mechanism of action of CC-1065 and the pyrrolo [1,4] benzodiazepines. Acc. Chem Res. (1986) 19:230–237.
   Google Scholar
• REYNOLDS VL, MCGOVERN JP, HURLEY LH: The chemistry, mechanism of actions and biological properties of CC-1065, a potent antitumor antibiotic. j Antibiot. (1986) 39:319–334.
   PubMed Web of Science ®Google Scholar
• ARISTOFF PA: CC-1065 Analogs: sequence specific DNA-alkylating antitumor agents. Adv. Med. Chem. (1993) 2:67–110.
   Google Scholar
• ••This review summarises the studies performed by Upjohn &Co. on CC-1065 and in particular the modifications on the right part of the molecule.
   Google Scholar
• BOGER DL, JOHNSON DS, YUN W, TARBY MC: Molecularbasis for sequence selective DNA alkylation by (+) and ent-(-)-CC-1065 and related agents: alkylation site models that accommodate the offset AT-rich adenine N3 alkylation selectivity. Bioorg. Med. Chem. (1994) 2:115–135.
   PubMedGoogle Scholar
• BOGER DL, JOHSON DS, YUN, W: (+)- andent-(-)-duocarmycin SA and (+)- and ent-(-)-N-Boc-DSA DNA alkylation properties. Alkylation site models that accommodate the offset AT-rich adenine N3 alkylation selectivity of enantiomeric agents. j Am. Chem. Soc. (1994) 116:1635–1656.
   Google Scholar
• BOGER DL, ISHISAKI T, ZARRINMAYEH H, KITOS PA, SUNTORNWAT O: Synthesis and preliminary evalua-tion of agents incorporating the pharmacophore of the duocarmycin/pyrindamycin alkylation subunit: identification of the CC-1065/duocarmycin common pharmacophore. J. Org. Chem. (1990) 55:4499–4502.
   Google Scholar
• BOGER DL, ISHIZAKI T, ZARRINMAYEH H, MUNK SA, KITOS PA, SUNTORNWAT O: Duocarmycin-pyrindamycin DNA alkylation properties and identifi-cations, synthesis and evaluation of agents incorpo-rating the pharmacophore of the duocarmycin-pyrindamycin alkylating subunit. Identification of the CC-1065-duocarmycin common pharmacophore. Am. Chem. Soc. (1990) 112:8961–8971.
   Google Scholar
• BOGER DL, ISHIZAKI T, ZARRINMAYEH H: Isolation and characyerization of duocarmycin-adenine DNA adduct. J Am. Chem. Soc. (1991) 113:6645–6649.
   Google Scholar
• •This report describes the isolation and the full characterisa-tion of the adduct between duocarmycin and DNA.
   Google Scholar
• BOGER DL, YUN W: Reversibility of the duocarmycin-A and SA DNA alkylation reaction./ Am. Chem. Soc. (1993) 115:9872–9873.
   Google Scholar
• BOGER DL, YUN W, TERASHIMA S, FUKUDA Y, NAKATANI K, KITOS PA, JIN Q: DNA alkylation proper-ties of the duocarmycins: (+)-duocarmycin A, Epi-(+)-duocarmycin A, Ent-(-)-duocarmycin A and Epi, Ent-(-)-duocarmycin A. Bioorg. Med. Chem. Lett. (1992) 2:759–765.
   Google Scholar
• SUGIYAMA H, HOSODA M, SAITO I, ASAI A, SAITO H: Covalent alkylation of DNA with duocarmycin A. Identification of abasic site structure. Tetrahedron Lett. (1990) 31:7197–7200.
   PubMedGoogle Scholar
• ASAI A, NAGAMURA S, SAITO H: A novel property of duocarmycin and its analogues for covalent reaction with DNA. J. Am. Chem. Soc. (1994) 116:4171–4177.
   Google Scholar
• SUGIYAMA H, OHMORI K, CHAN KL, HOSODA M, ASAI A, SAITO H et al.: A novel guanine N3 alkylation by antitumor antibiotic duocarmycin A. Tetrahedron Lett. (1993) 34:2179–2182.
   PubMedGoogle Scholar
• YAMAMOTO K, SUGIYAMA H, KAWANISHI S: Concerted DNA recognition and novel site-specific alkylation by duocarmycin A with distamycin A. Biochemistry (1993) 32:1059–1066.
   PubMedGoogle Scholar
• HURLEY LH, REYNOLDS VL, SWENSON GL, PETZOLD GL, SCAHILL TA: Reaction of the antitumor antibiotic CC-1065 with DNA: structure of DNA adduct with DNA sequence specificity. Science (1984) 226:843–844.
   PubMedGoogle Scholar
• ••This article describes the demonstration of the mechanismof action of CC-1065.
   Google Scholar
• NEEDHAM-VANDEVANTER DR, HURLEY LH, REYNOLDS VL, THERIAULT NY, KRUEGER WC, WIERENGA W: Characterization of an adduct between CC-1065 and a defined oligodeoxynucleotide duplex. Nucl. Acids Res. (1984) 12:6159–6168.
   PubMedGoogle Scholar
• REYNOLDS VL, MOLINEAUX IJ, KAPLAN DG, SWENSON DH, HURLEY LH: Reaction of the antitumor antibiotic CC-1065 with DNA. Location of the site of thermally induced strand breakage and analysis of DNA sequence specificity. Biochemistry (1985) 24:6228–6237.
   Google Scholar
• HURLEY LH, LEE CS, MCGOVERN JP et al.: Molecular basis for sequence-specific DNA alkylation by CC-1065. Biochemistry (1988) 27:3886–3892.
   PubMed Web of Science ®Google Scholar
• HURLEY LH, WARPEHOSKI MA, LEE CS et al.: Sequencespecificity of DNA alkylation by the unnatural enantiomer of CC-1065 and its synthetic analogues. J Am. Chem. Soc. (1990) 112:4633–4649.
   Web of Science ®Google Scholar
• UN CH, BEALE JM, HURLEY LH: Structure of the(+)-CC-1065-DNA adduct: critical role of ordered water molecules and implications for involvement of phosphate catalysis in the covalent reaction. Biochem-istry (1991) 30:3597–3602.
   PubMedGoogle Scholar
• WARPEHOSKI MA, HARPER DE, MITCHELL MA, MONROETJ: Reversibility of the covalent reaction of CC-1065 and analogues with DNA. Biochemistry (1992) 31: 2502–2508.
   PubMed Web of Science ®Google Scholar
• BOGER DL, COLEMAN RS, INVERGO BJ et al: Synthesis andevaluation of aborted and extended CC-1065 functional analogs: (+) and (-)-CPI-CDPIi and (+) and (-) CPI-CDPI3. Preparation of key partial structures and definition of an additional functional role of the CC-1065 central and right-hand subunits. J. Am. Chem. Soc. (1990) 112:4623–4632.
   Google Scholar
• BOGER DL, MUNK SA, ZARRINMAYEH H., ISHIZAKI T.,HAUGHT J, BINA M: An alternative and convenient strategy for generation of substantial quantities of singly 5'-32P-end labeled double stranded DNA for binding studies: development of a protocol for examination of functional features of (+)-CC-1065 and the duocarmycins that contribute to their sequence-selective DNA alkylation properties. Tetrahedron (1991) 47:2661–2682.
   Google Scholar
• BOGER DL, ZHOU J, CAI H: Demonstration and defini-tion of the noncovalent binding selectivity of agents related to CC-1065 by an affinity cleavage agent: noncovalent binding coincidental with alkylation. Bioorg. Med. Chem. (1996) 4:859–868.
   PubMedGoogle Scholar
• BOGER DL, ISHIZAKI T, KITOS PA, SUNTORNWAT O: Synthesis of N-(tert- Butyloxycarbony1)-CBI, CBI, CBI-CDPIi and CBI-CDPI2:enhanced functional analogues of CC-1065 incorporating the 1,2,9,9a-tetrahydrocyclopropa [c]benz[e]indo1-4-one (CBI) left hand subunit. J. Org. Chem. (1990) 55:5823–5832.
   Web of Science ®Google Scholar
• BOGER DL, JOHNSON DS: CC-1065 and the Duocarmycins: understanding their biological function through mechanistic studies. Angew. Chem. Intl. Ed. Engl. (1996) 35:1438–1474.
   Web of Science ®Google Scholar
• ••A very complete and extensive review on CC-1065 andduocarmycins.
   Google Scholar
• FREGEAU NL, WANG Y, PON TR, WYLIE AW, LOWN JW: Characterization of a CPI-lexitropsin conjugate-oligonucleotide covalent complex by 1H NMR and restrained molecular dynamics simulation. Am. Chem. Soc. (1995) 117:8917–8925.
   Google Scholar
• ••This article report the first hybrid between CPI and lexitrop-sin with high cytotoxicity.
   Google Scholar
• MCGOVERN JP, CLARKE GL, PRATT EA, DEKONING TF: Preliminary toxicity studies with the DNA-binding antibiotic, CC-1065. J. Antibiot (1984) 37:63–70.
   PubMedGoogle Scholar
• BOGER DL, ISHIZAKI T, KITOS PA, SUNTORNWAT O: Synthesis of N-(tert-butyloxycarbony1)-CBI, CBI, CBI-CDPI1 and CBI-CDPI2: enhanced functional analogues of CC-1065 incorporating the 1, 2, 9, 9a-tetrahydro cycloprop a [c]benz [e]in do1-4-one (CBI) left hand subunit. J. Org. Chem. (1990) 55:5823–5832.
   Web of Science ®Google Scholar
• BOGER DL, ISHIZAKI T: Resolution of a CBI precursorand incorporation into the synthesis of (+)-CBI,, (+)-C131-CDPI2; enhanced functional analogs of (+)-CC-1065. A critical appraisal of a proposed relationship between electrophile reactivity, DNA binding properties and cytotoxic potency. Tetrahedron Lett. (1990) 31:793–796.
   Google Scholar
• BOGER DL, MUNK SA, ISHIZAKI T: (+)-CC-1065 DNAalkylation: observation of an unexpected relationship between cyclopropane electrophile reactivity and the intensity of DNA alkylation. j Am. Chem. Soc. (1991) 113:2779–2780.
   Google Scholar
• BOGER DL, ISHIZAKI T, SAKYA SM et al.: Synthesis andpreliminary evaluation of (+)-CBI-Indole2:an enhanced functional analog of (+)-CC1065. Bioorg. Med. Chem. Lett. (1991) 1:115–120.
   Google Scholar
• BOGER DL, MCKIE JA, CAI H, CACCIARI B, BARALDI PG:Synthesis and properties of substituted CBI analogs of CC-1065 and the duocarmycins incorporating the 7-methoxy-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]in do1-4-one (MCBI) alkylation subunit: magnitude of electronic effects on the functional reactivity. j Org. Chem. (1996) 61:1710–1729.
   PubMed Web of Science ®Google Scholar
• BOGER DL, HAN N, TARBY CM, BOYCE CW, CAI H, JIN Q,KITOS PA: Synthesis, chemical properties and prelimi-nary evaluation of substituted CBI analogs of CC-1065 and the duocamycins incorporating the 7 -cyano-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]-indo1-4-one alkylation subunit: Hammet quantitation of the magnitude of electronic effects on functional reactivity. jOrg. Chem. (1996) 61:4894–4912.
   Google Scholar
• BOGER DL, MCKIE JA, HAN N, TARBY MC, RIGGS HW,KITOS PA: A Hammett correlation for CC-1065 and duocarmycin analogs-magnitude of substituent electronic effects on functional reactivity. Bioorg. Med. Chem. Lett. (1996) 6:659–664.
   Google Scholar
• BOGER DL, YUN W: Role of the CC-1065 and duocarmycin N2 substituent: validation of a direct relationship between solvolysis chemical stability and in vitro biological potency. J. Am. Chem. Soc. (1994) 1 1 6:5523–5524.
   Google Scholar
• ••This report summarises the studies performed with the aimto demonstrate the relationship between cytotoxicity and solvolytic stability of cyclopropane ring.
   Google Scholar
• BOGER DL, YUN W, HAN N: 1, 2, 9, 9a-Tetrahydrocyclo- propa[c]benz[e]indo1-4-one (CBI) analogs of CC-1065 and the duocarmycins: synthesis and evaluation. Bioorg. Med. Chem. (1 995 ) 3 :1429–1453 .
   Google Scholar
• BOGER DL, JENKINS TJ: Synthesis, X-ray structure and properties of fluorocyclopropane analogs of the duocarmycins inthe 9,9-difluoro-1,2,9,9a-tetrahydrocyclopropa[c]benzo[e]indo1-4-one (F2CBI) alkylation subunit. J. Am. Chem. Soc. (1996) 118:8860–8870.
   Google Scholar
• BOGER DL, TURNBULL P: Synthesis and evaluation of CC-1065 and duocarmycin analogs incorporating the A-hexahydrocyclopropa[c]naphtho [2,1-b]azepin-6-one (CNA) alkylation subunit - structural features that govern reactivity and reaction regioselectivity. Org. Chem. (1997) 62:5849–5863.
   Google Scholar
• BOGER DL, MÉSINI P, TARBY CM: Chemical and structural comparison of N- Boc-CBQ and N-Boc-CBI: Identification and structural origin of an unappreci-ated but productive stability of the CC-1065 and duocarmycin SA alkylation subunits." Am. Chem. Soc. (1994) 116:6461–6462.
   Google Scholar
• BOGER DL, BOYCE CW, GARBACCIO RM, GOLDBERG J: CC-1065 and the duocarmycins-synthetic studies. Chem. Rev. (1997) 97:787–828.
   PubMed Web of Science ®Google Scholar
• ••This review summarises all the synthetic approach for thesynthesis of CC-1065 and its derivatives.
   Google Scholar
• BOGER DL, GARBACCIO RM: Are the duocarmycin andCC-1065 DNA alkylation reactions acid catalyzed? Solvolysis pH-rate profiles suggest they are not. J. Org. Chem. (1999) 64:5666–5669.
   PubMedGoogle Scholar
• BARALDI PG, CACCIARI B, PINEDA DE LAS INFANTAS NJet al: Synthesis, chemical solvolytic stability and preliminary biological evaluation of (±)-n-boc-cpzi: a pyrazole analog of the left-hand segment of the antitumor agent CC-1065. AntiCancer Drug Des. (1997) 12:67–74.
   PubMedGoogle Scholar
• BARALDI PG, CACCIARI B, ROMAGNOLI R et al.:Synthesis, cytotoxicity, antitumor activity and sequence selective binding of two pyrazole analogs structurally related to the antitumor agents U- 71,184 and adozelesin. AntiCancerDrugDes. (1997) 12:555–576.
   Google Scholar
• BARALDI PG, CACCIARI B, ROMAGNOLI R, SPALLUTO G,BOYCE CW, BOGER DL: Resolution of a CPzI precursor, synthesis and biological evaluation of (+) and (-)-N-Boc-CPzI: a further validation of the relationship between chemical solvolytic stability and cytotoxicity. Bioorg. Med. Chem. Lett. (1999) 9:3087–3092.
   PubMedGoogle Scholar
• BOGER DL, GARBACCIO RM, JIN Q: Synthesis and evaluation of CC-1065 and duocarmycins analogues incorporating the iso-CI and iso-CBI alkylation subunits: impact of relocation of the C4 carbonyl. J Org. Chem. (1997) 62:8875–8891.
   Google Scholar
• BOGER DL, TURNBULL P: Synthesis and evaluation of carbocyclic analogue of the CC-1065 and duocarmycin alkylation subunits: role of the vinilogous amide and implications on DNA alkylation catalysis. J. Org. Chem. (1998) 63:8004–8011.
   Google Scholar
• MOHAMADI F, SPEES MM, STATEN GS et al: Total synthesis and biological properties of novel antineo-plastic (chloromethyl)furanoindolines: an asymmetric hydroboration mediated synthesis of the alkylation subunit. J. Med. Chem. (1994) 37:232–239.
   PubMedGoogle Scholar
• MURATAKE H, HAYAKAWA A, NATSUME M: A novel phenol-forming reaction for preparation of benzene, furan and thiophene anlogs of CC- 1065/ duocarmycins pharmacophore. Tetrahedron Lett. (1997) 43:7577–7580.
   Google Scholar
• PATEL VF, ANDIS SL, ENKEMA JK et al: Total synthesis of seco (+)- and ent-(-)-oxaduocarmycin SA: construction of the (chloromethyl)indoline alkylating subunit by a novel intramolecular aryl radical cyclization onto a vinyl chloride. J. Org. Chem. (1997) 62:8868–8874.
   Google Scholar
• MURATALE H, OKABE K, TAKAHASHI M, TONEGAWA M, NATSUME M: Synthesis of furan and thiophene analogs of duocarmycin SA. Chem. Pharm. Bull. (1997) 45:799–806.
   Google Scholar
• BARALDI PG, CACCIARI B, GUIOTTO A, ROMAGNOLI R,ZAID AN, SPALLUTO G: Heterocyclic analogs of DNA minor groove alkylating agents. CUIT. Pharm. Des. (1998) 4:249–276.
   PubMed Web of Science ®Google Scholar
• BOGER DL, BOYCE WC, GARBACCIO RM, SEARCEY M: Synthesis of CC-1065 and duocarmycin analogs via intramolecular aryl radical cyclization of a tethered vinyl chloride. Tetrahedron Lett. (1998) 39:2227–2230.
   Google Scholar
• BOGER DL, GARBACCIO RM: A novel class of CC-1065 and duocarmycin analogues subject to mitomycin-related reductive activation. J. Org. Chem. (1999) 64:8350–8362.
   PubMedGoogle Scholar
• BOGER DL, BOYCE CW: Selective metal cation activa-tion of a DNA alkylating agent: synthesis and evalua-tion of methyl 1, 2, 9, 9a-tetrahydrocyclo- propa[c] pyrido[3,2-e]indo1-4-one-7-carboxylate (CPyI). j Org. Chem. (2000) 65:4088–4100.
   PubMedGoogle Scholar
• BOGER DL, SANTILLAN JR A, SEARCEY M et al: Synthesis and evaluation of 1, 2, 8, 8a-tetrahydrocyclo-propa[c]pyrrolo[3,2-e]indo1-4(5H)-one, the parent alkylation subunit substituents and its implications for DNA alkylation catalysis. J. Org. Chem. (2000) 65:4101–4111.
   PubMedGoogle Scholar
• MILBANK JBJ, TERCEL M, ADWELL GJ, WILSON WR, HOGG A, DENNY WA: Synthesis of 1-substituted 3-(chloromethyl)-6-aminoindoline (6-amino-seco-CI) minor groove alkylating agents and structure activity relationships for the cytotoxicity. J Med. Chem. (1999) 42:649–668.
   PubMedGoogle Scholar
• ADWELL GJ, TERCEL M, BOYD, M, WILSON WR, DENNYWA: Synthesis and cytotoxicity of 5-amino-1-(chloro-methy1)34(5,6,7-trimethoxyindol-2-yl)carbonyli-1,2-dihydro-3H-benz[e]indole (amino-seco-CBIZIIVII) and related 5- alkylamino analogues: new DNA minor groove alkylating agents. J. Org. Chem. (1998) 63:9414–9420.
   Google Scholar
• TERCEL M, GIESEG MA, DENNY WA, WILSON WR: Synthesis and cytotoxicity of amino-seco-DSA: an amino analogue of the DNA alkylating agent duocarmycin SA. J Org. Chem. (1998) 64:5946–5953.
   Google Scholar
• WARPEHOSKI MA, GEZBHARD I, KELLY RC et al: Stereoe-lectronic factors influencing the biological activity and DNA interaction of synthetic antitumor agents modeled on CC-1065.j Med. Chem. (1988) 31:590–603.
   PubMedGoogle Scholar
• ARISTOFF PA, JOHNSON PD, SUN D, HURLEY LH: Synthesis and biochemical evaluation of the CBI-PDE-1-dimer, a benzannelated analog of (+)-CC-1065 that also produces delayed toxicity in mice. J Med. Chem. (1993) 36:1956–1963.
   PubMedGoogle Scholar
• BOGER DL, BOLLINGER B, HERTZOG DL et al: Reversedand sandwiched analogs of duocarmycin SA:establish-ment of the origin of the sequence-selective alkylation of DNA and new insights into the source of catalysis. J Am. Chem. Soc. (1997) 119:4987–4998.
   Google Scholar
• BOGER DL, YUN W, HAN N, JOHSON DS: CC-1065 analogs: an examples of enhancement of DNA alkyla-tion efficiency through introduction of stabilizing electrostatic interactions. Bioorg. Med. Chem. (1995) 3:611–621.
   PubMedGoogle Scholar
• BOGER DL, YUN W, CAI H, HAN N: CBI-CDPBOi and CBI-CDPBI1:CC-1065 analogs containing deep-seated modifications in the DNA binding subunit. Bioorg. Med. Chem. (1995) 3:761–775.
   PubMedGoogle Scholar
• BOGER DL, SANTILLAN JR A, SEARCEY M, JIN Q: Critical role of the linking amide in CC-1065 and the duocarmycins: implications on the source of DNA alkylation catalysis. J Am. Chem. Soc. (1998) 120:11554–11557.
   Google Scholar
• BOGER DL, SANTILLAN JR A, SEARCEY M, JIN Q: Synthesis and evaluation of duocarmycin and CC-1065 analogues containing modifications in the subunit linking amide. J Org. Chem. (1990) 64:5241–5244.
   Google Scholar
• BOGER DL, GARBACCIO RM: Shape-dependent catalysis: insight into the source of catalysis for the CC-1065 and duocarmycin DNA alkylation reaction. Acc. Chem. Res. (1999) 32:1043–1052.
   Google Scholar
• ••This report summarises all the studies performed in order tounderstand the mechanism of action of CC-1065, and duocarmycins and new considerations on the basis of recent experimental observations are reported.
   Google Scholar
• BOGER DL, CAI H: Bleomycin: Synthetic and mechanistic studies. Angew. Chem. Int. Ed. Egl. (1999) 38:449–476
   Google Scholar
• NAGAMURA S, ASAI A, AMISHIRO N, KOBAYASHI E, GOMI K SAITO H: Synthesis and antitumor activity of duocarmycin derivatives: A-ring pyrrole compounds bearing cinnamoyl groups. J. Med. Chem. (1997) 40:972–979.
   PubMedGoogle Scholar
• AMISHIRO N, NAGAMURA S, MURAKATA C et al.: Synthesis and antitumor activity of duocarmycin derivatives: modification at C-8 position of A-ring pyrrole compounds bearing the simplified DNA-binding groups. Bioorg. med. Chem. (2000) 8:381–391.
   PubMedGoogle Scholar
• HAY PM, SYKES BM, DENNY WA, WILSON WR: A 2-nitroimidazole carbamate prodrug of 5-amino-1-( chloromethyl)-3 -[(5,6,7 -trim eth ox yindol-2-yl)carbony1]-1,2-dihydro-3H-benz [e]in dole (amino-seco-CBI-11141) for use with ADEY1 and GDEY1. Bioorg. Med. Chem. Lett. (1999) 9:2237–2242.
   PubMed Web of Science ®Google Scholar
• •This article reports a new approach for ADEPT using CC-1065 derivatives.
   Google Scholar
• COTE S, MOMPARLER RL: Evaluation of the antineo-plastic activity of adozelesin alone and in combination with 5-aza-2'-deoxycytidine and cytosine arabinoside on DID-1 human colon carcinoma cells. AntiCancer Drugs (1993) 4:327–333.
   PubMed Web of Science ®Google Scholar
• LI LH, KELLY RC, WARPEHOSKI MA, MCGOVERN JP, GEBHARD I, DEKONING TF: Ado zelesin, a selected lead among cyclopropylpyrroloindole analogs of the DNA binding antibiotic, CC-1065. Inv. New Drugs (1991) 9:137–148.
   PubMedGoogle Scholar
• ••This article reports the pharmacological characterisation ofadozelesin.
   Google Scholar
• LI LH, DEKONING TF, KELLY RC et al: Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopro-pylpyrroloindole analogue. Cancer Res. (1992) 52:4904–4913.
   PubMed Web of Science ®Google Scholar
• ••This article reports the pharmacological characterisation ofcarzelesin.
   Google Scholar
• WALKER DL, REID JM, AMES MM: Preclinical pharma- cology of bizelesin, a potent bifunctional analog of the DNA-binding anCC-1065. Cancer Chemother.Pharmacol (1994) 34:317–322.
   PubMed Web of Science ®Google Scholar
• ••This article reports the pharmacological characterisation ofbizelesin.
   Google Scholar
• KOBAYASHI E, OKAMOTO A, ASADA M et al: Character- istics of antitumor activity of KW-2189, a novel water-soluble derivative of duocarmycin, against murine and human tumors. Cancer Res. (1994) 54:2404–2410.
   PubMed Web of Science ®Google Scholar
• ••This article reports the pharmacological characterisation of KW-2189.
   Google Scholar